UNSPSC 51382803: Clofezone anhydrous

This classification denotes the anhydrous form of a nonsteroidal antiinflammatory drug with the molecular formula C19H20N2O2.C14H21ClN2O2.2H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TPT3MH65LD, chemically known as 2-(4-chlorophenoxy)-n-(2-(diethylamino)ethyl)acetamide, compound with 4-butyl-1,2-diphenyltetrahydropyrazol-3,5-dione (1:1) but more generally known as clofezone, which bears US NIH Compound Identifier 6433695.

UNSPSC 51382803 Clofezone anhydrous is a Commodity code that in practice does not align with recent state and local procurement activity. The three most recent opportunities tagged to this code involve naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and over-the-counter products—none of which are clofezone anhydrous, a specific pharmaceutical ingredient. The mismatch suggests either tagging error or that state and local governments are not currently soliciting clofezone anhydrous as a standalone procurement item under this code.

The opportunities that do appear under the code span issuing bodies from Seminole County, Florida (a county health department procuring naloxone and deactivation systems via IFB 60459723LAS, due July 26, 2023), the Texas Health and Human Services Commission (issuing an RFI on direct-to-manufacturer prescription fulfillment, posted April 3, 2026), and the Minnesota Multistate Cooperative Purchasing Alliance (issuing an RFP for generic pharmaceuticals and OTC products across multiple state and local participants, due March 26, 2026). Geographic reach includes Florida, Texas, Minnesota, and Oregon. The absence of relevant clofezone anhydrous solicitations in the recent-opportunities block indicates minimal or no current procurement activity under this code for the named product.